Provention’s Teplizumab Can Delay Onset of Type 1 Diabetes, Trial Results Show

Shares of Provention Bio have soared more than 355% this morning after the New Jersey-based company announced its immunotherapy treatment to delay the onset of type 1 diabetes hit the mark in a clinical trial.